Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
NKGen Biotech (NKGN) has issued an update.
NKGen Biotech, Inc. has announced the appointment of Dr. Marco Gottardis as a Class I director, filling the vacancy left by Ms. Alana McNulty’s resignation. Dr. Gottardis, with a distinguished background in biopharmaceuticals, including leadership roles at Janssen Pharmaceuticals and consulting at Gottardis Biotech LLC, was also chosen to serve on the Audit, Compensation, and N&CG Committees. His appointment is accompanied by a compensation program and a stock option award, with no reported conflicts of interest or related party transactions.
Learn more about NKGN stock on TipRanks’ Stock Analysis page.
